Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results